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Dr C. Healey (Portland, Me): I assume you didn’t look at
prosthetic bypass or nonautologous veins in the NNE group
because the PREVENT trial didn’t have those patients. But did
you have an opportunity to look at that? Do you think if you took
people who got nonautogenous bypasses, would their results be
even poorer and would that be another score to put into your
decision-making tree?
Dr Schanzer. That is an interesting question. In the initial
iteration of this study we did include patients that had undergone
prosthetic bypasses and inclusion of these patients did not have any
significant effect on the results presented here. The model still
discriminated extremely well and provided similar 1 year estimates
for amputation free survival. As we further refined the current
study design, we felt that if we included prosthetic bypasses the
validation cohort would not be an appropriate comparison group
since the derivation study included a totally autogenous cohort. So
in order to maintain a clean and coherent study design, we ex-
cluded patients with prosthetic bypasses. Nonetheless, the answer
to your question is that it did not seem to alter the results in any
meaningful way.
DrW.Moore (Los Angeles, Calif): Your data clearly show that
your scorecard does discriminate between low, medium and high
risk patients. My question is, how do you plan to use this informa-
tion? Because even in your high risk patients, you had about a 53%
amputation-free survival. I hope you don’t plan to withhold treat-
ment in those patients even though theymay have a high risk score.
Dr Schanzer. I’m glad you brought up this very important
point. This question is one that, as investigators, we have struggled
with because you are absolutely right and we absolutely do not
wish to give the message that every single high risk patient should
be denied a surgical bypass procedure.
We feel that the PIII risk score is one tool that can be used to
help inform decision-making but that every individual patient mustpatients, a 50% 1 year amputation free survival may be considered
reasonable in light of the alternative options available. In other
patients, a 50% 1 year amputation free survival may not be consid-
ered reasonable. AS a result, we do not think that it is appropriate
to use this risk score to institute any broad sweeping guidelines.
Furthermore, our group is working on other prediction models for
other important endpoints such as quality of life, functional status
(i.e. ambulation), and non-composite endpoints such as mortality
and limb salvage. Ultimately all of these are going to have to be
used in concert. Unfortunately, one cannot create a single uber
model that encompasses all of these very relevant endpoints. Your
message is well stated and worth repeating– not every high risk
patient should be denied a bypass.
Dr M. Adelman (New York, NY): I wonder if there were
certain subgroups within the major groups (for instance, high risk
group) where specific interventions led to a better amputation-free
survival. In other words, are we going to start to indicate care for
different subgroups based on this data, or do the numbers get too
small as you break the data in smaller and smaller subsets?
Dr Schanzer. In brief, we have not further stratified the
groups beyond low, medium, and high risk as shown here. More-
over, all of these patients underwent autogenous vein bypass
surgery and no other types of revascularization procedures were
included in this analysis.
I think ultimately what you’re alluding to is that, as vascular
surgeons, we need to work towards developing the ability to better
identify which subgroups of patients will benefit from which spe-
cific treatment modality. In my opinion, the big challenge ahead of
us is to learn how to discriminate patient populations prospec-
tively. As we all know, there is a role for surgical bypass, there is a
role for endovascular intervention, and there is a role for primary
amputation. We need to get better at understanding how to apply
these techniques to the appropriate patient populations.
